Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 10/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488006 | 0.90 | KMT2A (0.47) | CSF1RSOS1TNFCXCL8NOD2 | |
| SCHEMBL17487358 | 0.86 | SOS1 (0.48) | CSF1RSOS1TNFCXCL8NOD2 | |
| SCHEMBL17487454 | 0.83 | CSF1R (0.50) | CSF1RSOS1TNFCXCL8NOD2 | |
| SCHEMBL17487426 | 0.81 | CXCL8 (0.50) | CSF1RSOS1TNFCXCL8NOD2 | |
| SCHEMBL18960417 | 0.80 | SMN1; SMN2 (0.43) | P2RX3KMT2AGRM4MEN1 | |
| SCHEMBL17487402 | 0.78 | ALDH1A1 (0.48) | CSF1RSOS1TNFCXCL8NOD2 | |
| SCHEMBL18960413 | 0.77 | CXCL8 (0.46) | CSF1RSOS1TNFCXCL8NOD2 | |
| SCHEMBL25275508 | 0.77 | MEN1 (0.55) | P2RX3KMT2AGRM4MEN1 | |
| SCHEMBL30466069 | 0.77 | MEN1 (0.55) | P2RX3KMT2AGRM4MEN1 | |
| SCHEMBL17487315 | 0.76 | SOS1 (0.59) | CSF1RSOS1TNFCXCL8NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | CSF1R 1559/4885SOS1 4452/4885TNF 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.